Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Chertsey, England – 24th October 2014 – Astellas Pharma Europe Ltd. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted...
Tokyo, Japan– October 22, 2014 – Astellas Pharma Inc. (TSE: 4503) (“Astellas”) announced the revision of the package insert for the oral androgen receptor signaling inhibitor XTANDI®...
Tokyo, Japan & South San Francisco CA, October 16, 2014 –Astellas Pharma Inc. (TSE: 4503) and CoMentis, Inc. today announced the companies will end their worldwide exclusive collaboration...
Tokyo, October 14th, 2014 --- Astellas Pharma Inc. (Tokyo: 4503, President & CEO: Yoshihiko Hatanaka, “Astellas”) announced today a research collaboration with an investigator at Harvard...
Follow us
